MX2019015544A - Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr). - Google Patents
Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr).Info
- Publication number
- MX2019015544A MX2019015544A MX2019015544A MX2019015544A MX2019015544A MX 2019015544 A MX2019015544 A MX 2019015544A MX 2019015544 A MX2019015544 A MX 2019015544A MX 2019015544 A MX2019015544 A MX 2019015544A MX 2019015544 A MX2019015544 A MX 2019015544A
- Authority
- MX
- Mexico
- Prior art keywords
- glp
- gipr
- treating
- receptor
- metabolic disorders
- Prior art date
Links
- 208000030159 metabolic disease Diseases 0.000 title abstract 5
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 101150020692 Gipr gene Proteins 0.000 title 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 230000002496 gastric effect Effects 0.000 title 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 108010011903 peptide receptors Proteins 0.000 title 1
- 102000014187 peptide receptors Human genes 0.000 title 1
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 abstract 2
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102000025171 antigen binding proteins Human genes 0.000 abstract 1
- 108091000831 antigen binding proteins Proteins 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000012743 protein tagging Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan métodos para el tratamiento de enfermedades y trastornos metabólicos mediante el uso de una composición que comprende una proteína de fusión de GLP-1/proteína de unión al antígeno para GIPR. En diversas modalidades, la enfermedad o trastorno metabólico es diabetes tipo 2, obesidad, dislipidemia, niveles elevados de glucosa, niveles elevados de insulina y nefropatía diabética. En determinadas modalidades, la composición comprende el extremo C de un análogo de GLP-1 fusionado con el extremo N de la región variable de cadena ligera o región variable de cadena pesada de un anticuerpo o fragmento funcional de este que se une a GIPR, opcionalmente con un conector entre medio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523216P | 2017-06-21 | 2017-06-21 | |
| PCT/US2018/038634 WO2018237095A1 (en) | 2017-06-21 | 2018-06-20 | METHOD OF TREATING OR ENHANCING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR AGONIST FUSION PROTEINS FROM THE GASTRIC INHIBITOR PEPTIDE RECEPTOR (GIPR) / GLP-1 RECEPTOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019015544A true MX2019015544A (es) | 2020-07-28 |
Family
ID=62904597
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015544A MX2019015544A (es) | 2017-06-21 | 2018-06-20 | Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr). |
| MX2023012010A MX2023012010A (es) | 2017-06-21 | 2019-12-18 | Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012010A MX2023012010A (es) | 2017-06-21 | 2019-12-18 | Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr). |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200384119A1 (es) |
| EP (2) | EP3642238A1 (es) |
| JP (1) | JP7250706B2 (es) |
| AU (2) | AU2018288852A1 (es) |
| CA (1) | CA3066251A1 (es) |
| MA (1) | MA49459A (es) |
| MX (2) | MX2019015544A (es) |
| WO (1) | WO2018237095A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018007859A (es) | 2015-12-23 | 2018-11-09 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1. |
| CN117003874A (zh) * | 2018-03-20 | 2023-11-07 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| CN112521501A (zh) * | 2019-09-18 | 2021-03-19 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| CN114685643A (zh) * | 2020-12-29 | 2022-07-01 | 苏州康宁杰瑞生物科技有限公司 | 一种人glp-1多肽变体及其应用 |
| CN114685644A (zh) * | 2020-12-29 | 2022-07-01 | 苏州康宁杰瑞生物科技有限公司 | 一种人glp-1多肽变体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| MX2018007859A (es) * | 2015-12-23 | 2018-11-09 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1. |
| JOP20190177A1 (ar) * | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
-
2018
- 2018-06-20 MA MA049459A patent/MA49459A/fr unknown
- 2018-06-20 MX MX2019015544A patent/MX2019015544A/es unknown
- 2018-06-20 CA CA3066251A patent/CA3066251A1/en active Pending
- 2018-06-20 JP JP2019566897A patent/JP7250706B2/ja active Active
- 2018-06-20 US US16/623,756 patent/US20200384119A1/en active Pending
- 2018-06-20 WO PCT/US2018/038634 patent/WO2018237095A1/en unknown
- 2018-06-20 EP EP18740407.4A patent/EP3642238A1/en active Pending
- 2018-06-20 EP EP24158632.0A patent/EP4353250A3/en active Pending
- 2018-06-20 AU AU2018288852A patent/AU2018288852A1/en active Pending
-
2019
- 2019-12-18 MX MX2023012010A patent/MX2023012010A/es unknown
-
2023
- 2023-12-11 AU AU2023282182A patent/AU2023282182A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023012010A (es) | 2023-11-24 |
| EP4353250A2 (en) | 2024-04-17 |
| AU2018288852A1 (en) | 2020-01-02 |
| MA49459A (fr) | 2020-04-29 |
| US20200384119A1 (en) | 2020-12-10 |
| EP3642238A1 (en) | 2020-04-29 |
| AU2023282182A1 (en) | 2024-01-04 |
| JP2020524661A (ja) | 2020-08-20 |
| JP7250706B2 (ja) | 2023-04-03 |
| WO2018237095A1 (en) | 2018-12-27 |
| CA3066251A1 (en) | 2018-12-27 |
| EP4353250A3 (en) | 2024-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012010A (es) | Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr). | |
| PH12019501656A1 (en) | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) | |
| MX2022011277A (es) | Proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1 para usarse en transtornos metabolicos. | |
| PH12017502025B1 (en) | Fusion proteins | |
| PE20080733A1 (es) | Proteinas de fusion de exendina | |
| EP3670534A3 (en) | Human fgf receptor and beta-klotho binding proteins | |
| JP2018519296A5 (es) | ||
| PH12019502603A1 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| WO2012170438A3 (en) | HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR | |
| NZ623541A (en) | Human cgrp receptor binding proteins | |
| AR079274A1 (es) | Proteinas de enlace a antigenos (humanas) que enlazan (beta)-klotho, receptores fgf y complejo de los mismos | |
| MX2021007444A (es) | Proteina biespecifica. | |
| EP3778634A4 (en) | GCGR ANTIBODY AND GLP-1 FUSION PROTEIN THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USES THEREOF | |
| EA201991583A1 (ru) | Способ лечения или облегчения метаболических нарушений с использованием белков, связывающих рецептор желудочного ингибиторного пептида (gipr), в комбинации с агонистами glp-1 | |
| AR107190A1 (es) | Método para tratar o aliviar trastornos metabólicos usando proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas del glp-1 |